MeTC7

SKU: orb1739329

Description

MeTC7 is a small molecule antagonist of the vitamin D receptor (VDR) that demonstrates antitumor properties by suppressing PD-L1. It has shown efficacy in inhibiting tumor growth in both xenograft and transgenic mouse models, making it a valuable tool for cancer immunotherapy and oncology research.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1817841-22-7
• MW: 618.65
• Purity: 99.69% (May vary between batches)
• Formula: C₃₂H₄₈BrN₃O₄
• SMILES: O=C1N2C34[C@@]([C@]5(C)C(N2C(=O)N1C)(C=C3)C[C@@H](OC(CBr)=O)CC5)(CC[C@@]6(C)[C@]4(CC[C@@]6([C@@H](CCCC(C)C)C)[H])[H])[H]
• Target: Vitamin
• Solubility: DMSO:20 mg/mL (32.33 mM);10% DMSO+90% Corn Oil:1 mg/mL (1.62 mM)

Bioactivity

• Target IC50:
  VDR:2.9 μM
• In Vivo:
  By intraperitoneal injection of 10 mg/kg MeTC7 was able to inhibit the growth of spontaneous transgenic TH-MYCN neuroblastoma and xenograft tumors in vivo.
  Read more...
• In Vitro:
  MeTC7 disrupts the VDR-Ligand-binding domain in Silico. MeTC7 shows potent VDR inhibition activity with an IC50=2.9 μM. Treatment with 250 nM MeTC7 for 18 h was able to inhibit the expression of RXRα and Importin-4 and induce PARP1 cleavage, thereby inhibiting the viability of ovarian cancer cells.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

MeTC 7, MeTC7, Miransertib dimesylate, Miransertib mesylate, VD

Compound Identifiers

PubChem CID

165437232